STUDY DESIGN: In 2 studies, the injection of chondroitinase ABC into intervertebral discs of mature goats was evaluated as an experimental disc degeneration model. The first study analyzed the development of degeneration in time; the second study determined the optimal enzyme concentration. OBJECTIVES: To develop reproducible, slowly progressive disc degeneration in a large animal model. SUMMARY OF BACKGROUND DATA: Currently available, small animal models of intervertebral disc degeneration have shortcomings in the comparability to humans in terms of size, geometry, and cell population. Also, the methods to induce degeneration in the current models do not mimic human degeneration, which starts with the loss of proteoglycans. Injecting the enzyme chondroitinase ABC into the nucleus pulposus mimics the loss of proteoglycans. METHODS: In Study 1, lumbar intervertebral discs of 17 goats were injected with chondroitinase ABC (0.25 U/mL) or phosphate-buffered saline. Degeneration was analyzed with radiograph analysis, MR imaging, and macroscopic and histologic scoring at 5 different time points (4, 8, 12, 18, and 26 weeks). Six control goats were analyzed. The second study used 6 goats in which 4 different concentrations of chondroitinase ABC (0.2-0.35 U/mL) or phosphate-buffered saline were injected. After 12 weeks, similar analyses as in Study 1 were performed. RESULTS: After 12 weeks, degenerative signs were observed in all parameters in Study 1. The degeneration increased up to 18 weeks and leveled off after 26 weeks. The variability, however, was high. The second study showed a concentration dependent effect of chondroitinase ABC with all analyzed parameters. The injection of 0.25 U/mL chondroitinase ABC resulted in disc degeneration after 12 weeks without signs of severe degeneration. CONCLUSION: Injection of chondroitinase ABC in the caprine intervertebral disc results in mild, slowly progressive disc degeneration. This effect was optimal at a concentration of 0.25 U/mL. This is a promising model of disc degeneration that deserves further study.
STUDY DESIGN: In 2 studies, the injection of chondroitinase ABC into intervertebral discs of mature goats was evaluated as an experimental disc degeneration model. The first study analyzed the development of degeneration in time; the second study determined the optimal enzyme concentration. OBJECTIVES: To develop reproducible, slowly progressive disc degeneration in a large animal model. SUMMARY OF BACKGROUND DATA: Currently available, small animal models of intervertebral disc degeneration have shortcomings in the comparability to humans in terms of size, geometry, and cell population. Also, the methods to induce degeneration in the current models do not mimic human degeneration, which starts with the loss of proteoglycans. Injecting the enzyme chondroitinase ABC into the nucleus pulposus mimics the loss of proteoglycans. METHODS: In Study 1, lumbar intervertebral discs of 17 goats were injected with chondroitinase ABC (0.25 U/mL) or phosphate-buffered saline. Degeneration was analyzed with radiograph analysis, MR imaging, and macroscopic and histologic scoring at 5 different time points (4, 8, 12, 18, and 26 weeks). Six control goats were analyzed. The second study used 6 goats in which 4 different concentrations of chondroitinase ABC (0.2-0.35 U/mL) or phosphate-buffered saline were injected. After 12 weeks, similar analyses as in Study 1 were performed. RESULTS: After 12 weeks, degenerative signs were observed in all parameters in Study 1. The degeneration increased up to 18 weeks and leveled off after 26 weeks. The variability, however, was high. The second study showed a concentration dependent effect of chondroitinase ABC with all analyzed parameters. The injection of 0.25 U/mL chondroitinase ABC resulted in disc degeneration after 12 weeks without signs of severe degeneration. CONCLUSION: Injection of chondroitinase ABC in the caprine intervertebral disc results in mild, slowly progressive disc degeneration. This effect was optimal at a concentration of 0.25 U/mL. This is a promising model of disc degeneration that deserves further study.
Authors: Yejia Zhang; Susan Drapeau; S An Howard; Eugene J M A Thonar; D Greg Anderson Journal: Spine (Phila Pa 1976) Date: 2011-03-01 Impact factor: 3.468
Authors: Stefan Schwan; Christopher Ludtka; Ingo Wiesner; Andre Baerthel; Andrea Friedmann; Felix Göhre Journal: Eur Spine J Date: 2017-10-27 Impact factor: 3.134
Authors: Yejia Zhang; Susan Drapeau; Howard S An; Dessislava Markova; Brett A Lenart; D Greg Anderson Journal: Spine (Phila Pa 1976) Date: 2011-09-01 Impact factor: 3.468
Authors: Benjamin Gantenbein; Svenja Illien-Jünger; Samantha C W Chan; Jochen Walser; Lisbet Haglund; Stephen J Ferguson; James C Iatridis; Sibylle Grad Journal: Curr Stem Cell Res Ther Date: 2015 Impact factor: 3.828
Authors: S E Gullbrand; N R Malhotra; T P Schaer; Z Zawacki; J T Martin; J R Bendigo; A H Milby; G R Dodge; E J Vresilovic; D M Elliott; R L Mauck; L J Smith Journal: Osteoarthritis Cartilage Date: 2016-08-26 Impact factor: 6.576
Authors: Suzanne E L Detiger; Roderick M Holewijn; Roel J W Hoogendoorn; Barend J van Royen; Marco N Helder; Ferco H Berger; Joost P A Kuijer; Theo H Smit Journal: Eur Spine J Date: 2014-08-05 Impact factor: 3.134